Allergy Therapeutics Share Discussion Threads

[totally banjo] 22/6/2025 14:26:04

That 'Long Term Chart' is pretty impressive over the two year period from the point of a solid long term investment!

[totally banjo] 22/6/2025 14:11:13

Edit- it looks like the same report released in May 2025



This looks like a new report or could be new and based on the report released back in May 2025 'U.S. Peanut Allergy Vaccine Market 2025-2032: Top Trends & Growth Drivers':

Peanut Allergy Vaccine Market to Witness Massive Growth by 2032 | Allergy Therapeutics, Zicam, Aravax, Immunomic Therapeutic
06-20-2025 04:27 PM CET | Health & Medicine

The latest report (2025-2032) on the Peanut Allergy Vaccine Market by Coherent Market Insights delivers a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.

//www.openpr.com/news/4006641/u-s-peanut-allergy-vaccine-market-2025-2032-top-trends

[totally banjo] 22/6/2025 13:48:26

This website was out a couple of days ago (I think it's legit) and from it links to 'Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects (PROTECT)' within a company called 'CTV' which appears to be dedicated to clinical trials.

From the opening page it states : 'Click below to learn more about how you may be able to help us in a new trial'


Anyway thought it was worth highlighting:

://peanutprotect.com/

[jimmyloser] 20/6/2025 11:51:08

I am happy to wait for 15 p Therapeutics, it sounds much better jpuff.

[jpuff] 20/6/2025 11:00:23

Maybe a renaming of the company to 7pTherapeutics would be appropriate?

[totally banjo] 14/6/2025 16:26:36

AGY really pushing the boat out at the EAACI event as they are also sponsoring (along with another)the Beat Allergy run!

hxxps://eaaci.org/events_congress/eaaci-congress-2025/wellbeing-activities-2/wellbeing-activities/

hxxps://x.com/EAACI_HQ/status/1933840169758490671

[totally banjo] 13/6/2025 19:40:38

Well I'm in trouble, still sat outside pub playing banjo as the sun goes down, doesn't get any better!

[totally banjo] 13/6/2025 12:30:44

This is a major event for AGY especially as they are relatively close in the completion of two potentially company changing products, if all goes to plan of course!

Hopefully get some media coverage after the event too.

[jpuff] 12/6/2025 16:29:31

The other issue of course is a fund raiser and a what cost or dilution like before?

[jpuff] 12/6/2025 14:42:39

Well the market normally knows best and gets the information before us plebs. So let's hope all goes to plan and the results are positive.

[jimmyloser] 12/6/2025 14:15:15

fwiw, my take is that the market is just waiting.......for 'confirmation'.....that our incredibly exciting new projects are on track....'confirmation' is all that is needed here.

I find it quite incredible that we are at last in the position that we are in.

dyor/impo etc

[totally banjo] 11/6/2025 12:47:52

EAACI Congress 2025
13 - 16 June 2025
Glasgow, United Kingdom


Allergy Therapeutics are exhibiting at this event with one of the bigger stalls (can't think of the right word!!) by the look:


hxxps://eaaci.org/wp-content/uploads/2025/02/Exhibition-Floor-Plan_Final_2June.pdf

[totally banjo] 11/6/2025 00:18:18

Been practicing pool ready for tomorrow, ooops todays game but the main point is:

"The award will be presented to Dr. Layhadi by María Jose Torres, President of EAACI, Mohamed Shamji, Secretary General of EAACI, Matthias Kramer, International Medical Director at Allergy Therapeutics, and Anke Graessel, Principal Medical Advisor Corporate at Allergy Therapeutics, at the opening ceremony of the EAACI Annual Congress 2025, Glasgow, UK, on Friday, 13 June. The congress will run until 16 June."

[totally banjo] 10/6/2025 14:56:42

Busy cutting grass today so will look later and see if AGY have any scientific papers or other activities at the EAACI Annual Congress 2025.

[totally banjo] 10/6/2025 13:45:46

Great publicity for AGY

[jimmyloser] 10/6/2025 09:15:46

NON RNS

Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")


Allergy Therapeutics and EAACI announce winner of EAACI Early Career Research Award



10 June 2025 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), today announces the winner of the EAACI Early Career Research Award.



The EAACI Early Career Research Award encourages young researchers and clinicians to push the boundaries in allergen immunotherapy research that can contribute to advancing allergy and immunology research and innovation, as future leaders in the field. The recipient of this year's award is Dr. Janice Layhadi, who is an early career researcher in the field of biomarker discovery in allergen immunotherapy.



Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "We are proud to support the EAACI Early Career Research Award and wish to congratulate the winner, Dr. Janice Layhadi, a rising star whose research is at the forefront of allergy and immunology research. Encouraging the next generation of researchers is vital to advancing our understanding of allergy and translating innovation into new therapeutic approaches that can meaningfully improve the lives of people living with allergies. Together with EAACI and through this award, we are committed to fostering scientific excellence that we hope will shape the future of allergy research and, ultimately, transform outcomes for patients."



María Jose Torres, President of the European Academy of Allergy and Clinical Immunology, said: "I would like to congratulate Dr. Janice Layhadi and extend my thanks to all the young researchers and clinicians for their applications this year. Recognising and supporting early-career researchers is fundamental to the advancement of the allergy research field and central to EAACI's mission. This award reinforces our commitment to fostering innovation, empowering the next generation of scientists and improving patient care."



Dr. Layhadi is a Research Associate at the Immunomodulation and Tolerance Group (ITG) of Allergy & Clinical Immunology, at Imperial College London's National Heart and Lung Institute. She completed her undergraduate studies in Biochemistry at Imperial College London and pursued a Master's degree in Pharmacology at Oxford University. Dr. Layhadi completed her PhD studies in molecular sciences and pharmacology at the University of East Anglia in 2017 and joined Professor Mohamed Shamji's group at Imperial College London. Her research interest primarily involves identifying underpinning molecular mechanisms that are induced following allergen immunotherapy and correlate with clinical efficacy.



Dr. Janice Layhadi said: "I am truly honoured to be the inaugural recipient of the EAACI Early Career Research Award. This recognition is both humbling and motivating, as it provides essential seed funding to generate the preliminary data critical for securing independent research support. With this award, I will continue to advance my investigations into the cellular and molecular mechanisms influenced by allergen-specific immunotherapy, using a comprehensive multi-omic approach. These opportunities are instrumental in supporting my transition to research independence."



The EAACI Early Career Research Award provides an unrestricted research grant of up to €30,000 and is open to EAACI Junior Members who have previously published their high-impact research on allergy and immunology and demonstrated their drive and dedication in the area of immunotherapy. The planned research is expected to contribute to a better understanding of allergic inflammation as well as improved diagnostic procedures and treatment, enabling improved patient management and patient satisfaction.



The award will be presented to Dr. Layhadi by María Jose Torres, President of EAACI, Mohamed Shamji, Secretary General of EAACI, Matthias Kramer, International Medical Director at Allergy Therapeutics, and Anke Graessel, Principal Medical Advisor Corporate at Allergy Therapeutics, at the opening ceremony of the EAACI Annual Congress 2025, Glasgow, UK, on Friday, 13 June. The congress will run until 16 June.



- ENDS -





Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]



Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

[phone]



ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]





Notes for editors:



About Allergy Therapeutics



Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more in

[totally banjo] 06/6/2025 11:00:18

Without rekindling the family feud, I enjoy both :-)

[jimmyloser] 06/6/2025 07:28:03

Lol, Banjo, I actually like your post pub posts. They usually have a quirky perspective to them. Are they inspired by Black Sheep or Theakstons ? :-)

[totally banjo] 06/6/2025 00:35:26

While I was carrying out my gardening work yesterday I got wondering when the next news from AGY is likely, so I've had a quick look (It's okay jimmy, I haven't just returned from pub)

The next point of interest is the Proactive One2One Investor Forum taking place in London on the 24th of this month. It's possible AGY have some news warranting an RNS prior to this event but purely guess work on my part.




Regarding the peanut vaccine (PROTECT trial)in the USA they have stated (March 2025) that:

"The PROTECT trial continues to progress to plan and the Company expects to announce the initial topline data later this summer." so not long to wait for that update!

hxxps://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=16396761


Regarding the Grass MATA MPL- Not sure an update is on the cards for a few more months but you never know....

[jimmyloser] 30/5/2025 14:50:12

Please forgive if previously posted......

[totally banjo] 28/5/2025 12:53:20

Another report:

Allergy Treatment Market Set to Grow at 6-7% CAGR: Key Trends, Challenges, and Opportunities by 2029
26-May-2025

"The global allergy treatment market is marked by the presence of established and emerging market players such as Johnson & Johnson; Allergopharma; Sanofi SA; Genentech Inc.; GlaxoSmithKline PLC; Leti Pharma; Allergy Therapeutics PLC;"

hxxps://www.pharmiweb.com/press-release/2025-05-26/allergy-treatment-market-set-to-grow-at-6-7-cagr-key-trends-challenges-and-opportunities-by-2029

[totally banjo] 27/5/2025 18:35:47

Steady away! This is the most boring stock I've ever held but with very very exciting prospects over the next six months or so....

Saying that we should get some updates between this timeframe which potentially could see a lot of interest!